Fabrice André

Fabrice André, MD, PhD is Professor and Head of the Department of Medical Oncology at Gustave Roussy Cancer Campus in Paris, France, where he also serves as Director of Research. He is one of Europe's most prominent translational oncologists and has defined the molecular landscape of endocrine resistance in HR+ breast cancer. Dr. André's most influential contribution has been the characterization of ESR1 ligand-binding domain mutations as the dominant mechanism of acquired resistance to aromatase inhibitor therapy, establishing liquid biopsy detection of ESR1 mutations as both a clinical biomarker and a therapeutic target. He led pivotal preclinical and early clinical work supporting the development of oral selective estrogen receptor degraders (SERDs), and is the global principal investigator of the SERENA-6 trial, a landmark ctDNA-guided adaptive trial in which patients detected to have ESR1 mutations on liquid biopsy are randomized to switch to camizestrant (an oral SERD) or continue standard therapy. Dr. André also spearheaded the SAFIR02_BREAST trial, demonstrating the feasibility of genomic-guided treatment allocation in metastatic breast cancer. He is past editor-in-chief of Annals of Oncology and a founding contributor to the European ESMO Translational Research and Precision Medicine Working Group. He has published more than 400 peer-reviewed articles and is among the most cited scientists in breast cancer translational research globally.